Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who is speaking on behalf of CYDY at CROI?
My great hope is that it is anyone other than Pourhassan who, to put it charitably, does not present well.
Rehashing results of 10 patient study won't move SP. What is needed are results from a different study, BTD, or something else that is new and exciting.
It would also help if someone other than Pourhassan, with more pharm-cred, made the presentation at CROI.
Even better would be to terminate Pourhassan as this would send a strong signal to the market that CYDY is gearing up to take the next step in its development.
Results from two Phase II clinical trials are expected in 1H 2017, which can mean anytime now.
If, as expected, the results of these clinical trials establish that encochleation of effective but toxic drugs--that must be administered intravenously in a hospital--can be safely and effectively administered orally, Big Pharma should line up to partner with or buy out this $20M company.
Supplementing Pourhassan with Carracciolo is a good start. However, Pourhassan does not have the knowledge, background, or experience to be involved in the management of a clinical stage biopharma company such as Cytodyn, and should be replaced with someone who possesses such qualities. The .75 stock price, for a company in multiple Phase III trials for a much needed monoclonal antibody that could become the SOC for HIV, conclusively demonstrates the market (and likely FDA) lacks confidence in Cytodyn's current CEO.
If MTNB strings together 10 consecutive days of a $2 share price, the company can uplist to NYSE Market. This should be a major catalyst, along with the results of the two clinical trials expected to be announced in the next few months. Big things appear to be on the horizon for this exciting company.
Many clinical stage biopharma companies have seasoned executives running them. CYDY's inexperienced and unqualified president is the exception rather than the rule.
CYDY's previous BTD request was denied for lack of data. Hopefully, management has learned from this mistake, and will provide the FDA with sufficient data to support the new BTD application.
While Pourhassan is unqualified his nationality is irrelevant.
I agree with Blue Horseshoe that attacking Pourhassan based upon his nationality is improper and offensive. However, for reasons other than his nationality, Pourhassan is unqualified to run this or any other company.
There is nothing in Pourhassan's background or experience that would qualify him to run a clinical stage biotech company, while the way he comports himself in public appearances does not inspire confidence in management or the company.
IMHO, CYDY would do much better with a more qualified president at the helm.
Matinas receives $12.8M for warrants tendered.
Matinas announced today that 84% of all warrant holders tendered their warrants for a net to the company of $12.7M. Matinas further announced that this cash runway will take them to 2018.
By that time, Matinas will have announced results of its Phase 2a clinical study for encochleated amphotericin b, and the Phase 1 clinical study for encochleated amikacin, both of which are expected in 1H 2017, and will be well into Phases 3 and 2, respectively, for these two drugs.
If the Phase 2a and 1 clinical trials show encochleated amphotericin b, and encochleated amikacin, to be safe and effective, a partnership or buy out would appear to be likely.
I own a lot of CYDY stock,and have no intention of selling. However, I would like to make money on this investment, which is why I would like to have someone competent running the company.
If enough shareholders say no mas, then Pourhassan would be replaced.
It is far more likely that directors, or members of the SAB, are communicating with the FDA on the company's behalf as Pourhassan does not have the scientific background that would enable him to be able to intelligently communicate on the FDA level.
Not only does Pourhassan have no skin in the game, he is being paid over $600,000 per year, per the 2015 10-K, plus warrants. For that kind of money, we could have a president with biopharma experience who has successfully navigated the FDA waters, and brought a clinical stage company to the point of being bought out.
One other good thing about Dr.Burger is that he is affable and well-spoken, two things Pourhassan most definitely is NOT. If you have spoken to both Pourhassan and Dr. Burger as I have, you would wonder why the former is president.
Gestalt:
In my opinion, Pourhassan is too arrogant to admit someone is better qualified than him to run the company. Despite having talented people on the board, the company and its stock continue to flounder. With such a potentially great product in PRO 140, this is a shame. If Pourhassan were to be replaced now, shareholder confidence would be restored, and the stock price would increase dramatically.
LM
Pears:
You have every right to be concerned about Pourhassan as he is not qualified to run this company.
Every shareholder who has an interest in making money on their investment in Cytodyn should share your concern.
With so much that could happen in the coming months, the time is right to replace Pourhassan that can take the company to the next level.
I would suggest that you and any other shareholder who shares your concern contact every board member, and demand that Pourhassan be replace.
Gestalt:
I have spoken at length with Dr. Denis Burger, Cytodyn's vice-chairman and CSO, who is an extremely bright and affable man. It was Dr. Burger who convinced me to invest in Cytodyn.
Dr. Burger has successfully headed up a number of successful start up biotech companies, and is far more qualified than Pourhassan to run Cytodyn, in my opinion. I would be delighted if Dr. Burger replaced Pourhassan.
It is we the shareholders who decide who sits on the board.The board,in turn, decides who serves as president. If we the shareholders put pressure on the board to replace Pourhassan, with Dr. Burger, or someone else more qualified than Pourhassan to run the company, we can make it happen. With a new and more competent president in charge of the company, we all stand to benefit from the success that will ensue from a much needed changing of the guard.
I agree with Broker57: Pourhassan must go.
It is not merely that Pourhassan is not qualified to take PRO 140 to the finish line, and does not have the intellect or temperment to speak well on behalf of the company, but he is also grossly overpaid.
Pourhassan no doubt wants the company to succeed, as he holds a significant amounts of warrants. However, there is nothing in his background or experience which suggests he has the ability to make Cytodyn a successful company.
Moreover, if you have ever listened to any of the shareholder or analyst calls Pourhassan has hosted,or better yet, spoke to him personally, you would conclude he is the wrong man for the job as he is not well-spoken,gets angry when challenged, and does not present well.
This is not about bashing or pumping, but the reality of the situation we as shareholders face.PRO 140 has tremendous potential. However, the success of this company, like most, rests on the ability of management to direct the company properly.
Put PRO 140 in the hands of an executive who has a history of obtaining FDA approval of a clinical stage drug, and then getting the company sold to Big Pharma, and shareholder confidence would be restored, and the stock price would languish at around 70 cents.
I am very heavily invested in CYDY, and very much want it to succeed. However, I think the chances of success are greatly diminished by having an underqualified and overcompensated president at its helm.
My position is sizable,which is why I so badly want to see Pourhassan replaced with a competent,fairly compensated, experienced CEO. My only "agenda" is for the company to be successful, so PRO 140 will be approved, and I will make money. If I thought Pourhassan was the right man for the job, I would be 100% in his corner. The only reason I want Pourhassan to be replaced is I think he is underqualified and overcompensated.
Darned right! Pourhassan should be replaced IMMEDIATELY. There is a huge difference between trying hard and succeeding. If you listen to the update conference calls run by Pourhassan, or speak with him directly,and I have done both, you must come to the conclusion that he is in way over his head. For the millions per year Pourhassan is paid, Cytodyn could get a seasoned executive wih a history of success in bringing clinical stage biopharma companies to the finish line. If you think with your wallet,rather than your heart, you must agree that Cytodyn should replace Pourhassan now.
Pears:
I could not agree with you more.
Pourhassan is incompetent,and has to go.
To make matters worse, Pourhassan is being paid millions of dollars per year.
For that kind of money, Cytodyn could attract a top talent to run the company.
Any idea on what we shareholders can do to get our incompetent and overpaid president replaced?
Pourhassan must be replaced now. Regardless of how or why Pourhasssan got the job as Cytodyn's president, he should not be allowed to retain this job now as he does not have the experience,intellect, or disposition to bring this company to the finish line. Even worse, he is GROSSLY overpaid to the tune of millions of dollars per year. For that kind of money, Cytodyn could get a seasoned professional who has had a history of successes with clinical stage biopharma companies such as this.
Pourhassan is grossly overpaid and should be replaced. Although company president, Nader Pourhassan, does not have the experience, intellect, or temperment to run a clinical stage biophrama company, he is being paid millions of dollars a year to run Cytodyn. The prospects for this company would be greatly enhanced if Pourhassan were to be replaced with someone with the competence and temperment that Pourhassan sorely lacks.
Pourhassan needs to be replaced NOW. This guy has to be the most overpaid ceo of any clinical stage biopharma in the country. How this guy warrants a multi-million dollar annual compensation package is mind boggling. There is nothing in his background or experience that would suggest he is capable of succeeding at this level. Anypone who has heard Pourhassan on a conference call knows he does not have the temperment, savvy, or intelligence to successfully run this company. Although I believe in the science, I have no confidence in Pourhassan, and would hope he is soon replaced with someone more competent. The only way Pourhassan will ever be replaced is if shareholders demand it. If someone knows the mailing and email addresses for Cytodyn's board members, please post them so we shareholders can contact the board members and demand that Pourhassan be replaced.
I agree with your assessment Cars100.
The cochleate technology appears to be a safe platform for delivery of many highly effective drugs that have limited utility because they are so toxic.
If proven to be the case, this could be a multi-billion dollar company.
So why is Matinas languishing at such low levels, and what will be the catalyst for an increased market cap?